SLC22A1 and cancer: Studies have showed that Oct-1 was abnormally expressed in a variety of cancers and the overexpression of Oct-1 was associated with the poor prognosis in well-differentiated gastric adenocarcinoma patients (Jeong et al., 2014; Rhodes et al., 2007).